Marpai (NASDAQ:MRAI) versus BioRestorative Therapies (NASDAQ:BRTX) Head-To-Head Comparison

BioRestorative Therapies (NASDAQ:BRTX) and Marpai (NASDAQ:MRAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for BioRestorative Therapies and Marpai, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioRestorative Therapies	0	0	0	0	N/A
Marpai	0	1	0	0	2.00

Insider and Institutional Ownership

6.9% of BioRestorative Therapies shares are owned by institutional investors. Comparatively, 8.9% of Marpai shares are owned by institutional investors. 21.6% of BioRestorative Therapies shares are owned by insiders. Comparatively, 39.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares BioRestorative Therapies and Marpai’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioRestorative Therapies	$130,200.00	65.07	-$18.50 million	N/A	N/A
Marpai	$36.08 million	0.20	-$26.47 million	($5.40)	-0.17

BioRestorative Therapies has higher earnings, but lower revenue than Marpai.

Profitability

This table compares BioRestorative Therapies and Marpai’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	-12,195.10%	-117.00%	-110.65%
Marpai	-89.28%	-6,218.15%	-75.12%

Volatility & Risk

BioRestorative Therapies has a beta of 62.09, meaning that its share price is 6,109% more volatile than the S&P 500. Comparatively, Marpai has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Summary

Marpai beats BioRestorative Therapies on 5 of the 9 factors compared between the two stocks.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

About Marpai

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, bill review and cost containment services. It also develops artificial intelligence and healthcare technology. Marpai, Inc. was incorporated in 2021 and is headquartered in New York, New York.